David Colpman joins Forendo Pharma’s Board of Directors

His previous roles include Head of Global Business Development at Shire and business development and commercial positions at Glaxo Wellcome and Novo Nordisk. David has a degree in Pharmacy and he also serves on the Boards of Orexo AB and HRA Pharma Ltd

Forendo Pharma is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometriosis lesions. The key differentiator of the company’s lead HSD17B1 inhibitor, FOR-6219, compared to other drug treatments in the market or in clinical development is the ability to act locally without impacting the systemic estrogen levels, as demonstrated in preclinical models. Forendo’s first in class compound with selective activity is expected to allow safer long-term treatment of this chronic disease without harmful symptoms of estrogen deficiency, that are seen with current treatment options for endometriosis. The company’s lead program is entering phase I studies in 2018. The second program of Forendo, Dual HSD Inhibitor, currently in discovery phase, offers additional opportunities in women’s health indications, including endometriosis.